The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy

Ugur Ozerdem University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

Beata Mach-Hofacre University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

Lingyun Cheng University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

Sunan Chaidhawangul University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

Kelly Keefe University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

Charles D. McDermott University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

Germaine Bergeron-Lynn University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

Krzysztof Appelt University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

William R. Freeman University of California, San Diego, Shiley Eye Center, San Diego, CA, USA, U.S. Navy Hospital, Department of Ophthalmology (Ophthalmic Pathology), San Diego, CA, USA, 3Agouron Pharmaceuticals, Inc., San Diego, CA, USA

show all

Abstract

Purpose. To determine the efficacy of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinase, in the treatment of experimental proliferative vitreoretinopathy (PVR) induced by intravitreal dispase injection. Methods. One eye each of 53 New Zealand white rabbits was injected in the vitreous cavity with 0.07 unit of dispase to induce PVR. One week after PVR induction, 53 rabbits were randomized (27:26) to receive 0.5 mg prinomastat or the vehicle of the drug (acidified water) intravitreally every two weeks. The scores of PVR severity (scale of 1–5) were graded to compare the prinomastat-treated animals with the control group. Results. The average PVR scores in the treatment and control groups were 2.62 and 3.57 respectively (p = 0.038; Wilcoxon rank sum). Clinically significant PVR with retinal detachment (PVR = grade 3) developed in 76% of rabbits in the control group versus 51% of rabbits treated with prinomastat. Conclusions. Intravitreally administered prinomastat decreased development of PVR in an experimental model which made use of dispase to induce PVR.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy

Information for

Open access

Opportunities

Help and information

The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature